1822.HK
China wood turns losses into profits

The Latest: China Wood International Holding Co. Ltd. (1822.HK) announced on Thursday that it earned a profit of HK$1.2 billion ($153 million) last year, while its revenue rose 122% to HK$323 million.

Looking Up: China Wood conducted a successful restructuring last year, and as a result a court that was overseeing its liquidation after the company experienced earlier financial difficulties believes such a liquidation is no longer necessary.

Take Note: The profit mainly came from sales and cash received as part of the restructuring, which generated approximately HK$1.27 billion.

Digging Deeper: China Wood was established in 2009 and mainly operates wood-related businesses and car rentals, though it is considering exiting the latter. Its shares were suspended earlier this week as the company prepared to announce its latest annual results following a major restructuring last year. In addition to its core business in wood, the company plans to enter the health food and beverage industry in response to rapid growth in demand for such products post-pandemic. It is considering fund-raising to help pay for such efforts after its restructuring.

Market Reaction: China Wood’s stock opened sharply higher on Friday as it resumed trading, rising nearly three times at one point. It closed at HK$0.125, up 257%, by the midday break.

To subscribe to Bamboo Works free weekly newsletter, clickhere

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…